Developing a Prognostic Micro-RNA Signature for Human Cervical Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 17

PMID 25880806

Citations 21

Authors

Christine How

Melania Pintilie

Jeff P Bruce

Angela B Y Hui

Blaise A Clarke

Philip Wong

Shaoming Yin

Rui Yan

Daryl Waggott

Paul C Boutros

Anthony Fyles

David W Hedley

Richard P Hill

Michael Milosevic

Fei-Fei Liu

Affiliations

Soon will be listed here.

Abstract

Cervical cancer remains the third most frequently diagnosed and fourth leading cause of cancer death in women worldwide. We sought to develop a micro-RNA signature that was prognostic for disease-free survival, which could potentially allow tailoring of treatment for cervical cancer patients. A candidate prognostic 9-micro-RNA signature set was identified in the training set of 79 frozen specimens. However, three different approaches to validate this signature in an independent cohort of 87 patients with formalin-fixed paraffin-embedded (FFPE) specimens, were unsuccessful. There are several challenges and considerations associated with developing a prognostic micro-RNA signature for cervical cancer, namely: tumour heterogeneity, lack of concordance between frozen and FFPE specimens, and platform selection for global micro-RNA expression profiling in this disease. Our observations provide an important cautionary tale for future miRNA signature studies for cervical cancer, which can also be potentially applicable to miRNA profiling studies involving other types of human malignancies.

Citing Articles

CESCProg: a compact prognostic model and nomogram for cervical cancer based on miRNA biomarkers.

Muthamilselvan S, Palaniappan A PeerJ. 2023; 11:e15912.

PMID: 37786580 PMC: 10541812. DOI: 10.7717/peerj.15912.

The Potential microRNA Prognostic Signature in HNSCCs: A Systematic Review.

Dioguardi M, Spirito F, Iacovelli G, Sovereto D, Laneve E, Laino L Noncoding RNA. 2023; 9(5).

PMID: 37736900 PMC: 10514860. DOI: 10.3390/ncrna9050054.

Disease progression role as well as the diagnostic and prognostic value of microRNA-21 in patients with cervical cancer: A systematic review and meta-analysis.

Gebrie A PLoS One. 2022; 17(7):e0268480.

PMID: 35895593 PMC: 9328569. DOI: 10.1371/journal.pone.0268480.

Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.

Veryaskina Y, Titov S, Zhimulev I Med Princ Pract. 2022; 31(4):322-332.

PMID: 35354155 PMC: 9485981. DOI: 10.1159/000524283.

Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.

Liu W, Jiang Q, Sun C, Liu S, Zhao Z, Wu D BMC Cancer. 2022; 22(1):192.

PMID: 35184747 PMC: 8859909. DOI: 10.1186/s12885-022-09291-z.

References

Liu N, Chen N, Cui R, Li W, Li Y, Wei R . Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. DOI: 10.1016/S1470-2045(12)70102-X. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Chang A, Grignon D, Keeney M, Koster J, Kirk M . DNA content in cervical carcinoma: a flow cytometric assessment of DNA heterogeneity. Int J Gynecol Pathol. 1994; 13(4):330-6. DOI: 10.1097/00004347-199410000-00006. View

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

Harfe B . MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005; 15(4):410-5. DOI: 10.1016/j.gde.2005.06.012. View

de Biase D, Visani M, Morandi L, Marucci G, Taccioli C, Cerasoli S . miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time pCR. PLoS One. 2012; 7(4):e35596. PMC: 3329457. DOI: 10.1371/journal.pone.0035596. View

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L . Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002; 20(3):680-7. DOI: 10.1200/JCO.2002.20.3.680. View

Kolbert C, Feddersen R, Rakhshan F, Grill D, Simon G, Middha S . Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS One. 2013; 8(1):e52517. PMC: 3561362. DOI: 10.1371/journal.pone.0052517. View

10.

Koopman L, Corver W, van der Slik A, Giphart M, Fleuren G . Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med. 2000; 191(6):961-76. PMC: 2193119. DOI: 10.1084/jem.191.6.961. View

11.

Raychaudhuri M, Schuster T, Buchner T, Malinowsky K, Bronger H, Schwarz-Boeger U . Intratumoral heterogeneity of microRNA expression in breast cancer. J Mol Diagn. 2012; 14(4):376-84. DOI: 10.1016/j.jmoldx.2012.01.016. View

12.

Waggott D, Chu K, Yin S, Wouters B, Liu F, Boutros P . NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012; 28(11):1546-8. PMC: 3356845. DOI: 10.1093/bioinformatics/bts188. View

13.

Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X . Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008; 68(1):26-33. DOI: 10.1158/0008-5472.CAN-06-4418. View

14.

Alajez N, Lenarduzzi M, Ito E, Hui A, Shi W, Bruce J . MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011; 71(6):2381-91. DOI: 10.1158/0008-5472.CAN-10-2754. View

15.

Weng L, Wu X, Gao H, Mu B, Li X, Wang J . MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol. 2010; 222(1):41-51. DOI: 10.1002/path.2736. View

16.

Guo Z, Wu F, Asplund A, Hu X, Mazurenko N, Kisseljov F . Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod Pathol. 2001; 14(2):54-61. DOI: 10.1038/modpathol.3880256. View

17.

Wang X, Tang S, Le S, Lu R, Rader J, Meyers C . Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008; 3(7):e2557. PMC: 2438475. DOI: 10.1371/journal.pone.0002557. View

18.

Park N, Zhou H, Elashoff D, Henson B, Kastratovic D, Abemayor E . Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15(17):5473-7. PMC: 2752355. DOI: 10.1158/1078-0432.CCR-09-0736. View

19.

Nonn L, Vaishnav A, Gallagher L, Gann P . mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol. 2009; 88(1):45-51. PMC: 2815196. DOI: 10.1016/j.yexmp.2009.10.005. View

20.

Lyng H, Vorren A, Sundfor K, Taksdal I, Lien H, Kaalhus O . Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy. Int J Cancer. 2001; 96(3):182-90. DOI: 10.1002/ijc.1019. View